| 79614-02-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• CAS: 79614-02-1
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: GKPFKDSEWDXQAF-CMDGGOBGSA-N

物化性质

• 沸点：
  154.8±9.0 °C(Predicted)
• 密度：
  0.78±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.51
• 重原子数：
  9.0
• 可旋转键数：
  2.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  12.36
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为产物：
  描述：

  N-(3-bromo-3-methyl-2-butylidene)isopropylamine 在 甲醇 、 tin(ll) chloride 作用下， 反应 4.0h， 生成
  参考文献：
  名称：

  Aelterman; Eeckhaut; De Kimpe, Synlett, 2000, # 9, p. 1283 - 1284

  摘要：

  DOI：

文献信息

• AGRICULTURAL CHEMICALS
  申请人：Redx Pharma Ltd.

  公开号：US20150094474A1

  公开（公告）日：2015-04-02

  The present invention relates to derivatives of compounds which are known to be of use in the field of agriculture. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more changes one or more of which may be considered to represent a change of oxidation state relative to the groups in the original compound. We refer to these compounds generally as redox derivatives. The compounds are of use as insecticides, herbicides and insect repellents.

  本发明涉及与农业领域中已知有用的化合物衍生物。这些衍生物通过成为活性化合物的氧化还原衍生物而与母体活性化合物区分开来。这意味着活性化合物中的一个或多个官能团已经转化为另一个官能团，其中一个或多个转变可能被认为代表相对于原始化合物中的官能团的氧化状态的变化。我们通常将这些化合物称为氧化还原衍生物。这些化合物可用作杀虫剂、除草剂和驱虫剂。
• Organometallic reactions of α-haloimines as a useful tool in organic synthesis
  作者：Norbert de Kimpe、Bart de Corte、Roland Verhe、Laurent de Buyck、Niceas Schamp

  DOI：10.1016/s0040-4039(01)80111-8

  日期：1984.1

  The reaction of organometallic reagents, e.g. alkyllithiums, cuprates and alkylcoppers, with α-haloimines gave selectively a variety of synthetically useful reactions, including coupling to 1,4-diimines, homologation, and production of heterocycles.

  有机金属试剂（例如烷基锂，铜酸盐和烷基铜）与α-卤代亚胺的反应选择性地产生了多种合成上有用的反应，包括与1,4-二亚胺的偶联，同系物和杂环的产生。
• HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20150274738A1

  公开（公告）日：2015-10-01

  Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L 1 represents a linker; and R H represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.

  提供的是公式（I）的双功能小分子或其药学上可接受的盐，其中M代表结合激酶的小有机分子，可以是共价或非共价结合，例如Her3蛋白激酶；L1代表连接物；RH代表疏水基团。公式（I）的一个化合物示例是公式（II）的化合物： 还提供了包含公式（I）或（II）化合物的药物组合物，以及使用这些化合物治疗增殖性疾病的方法。
• TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US20150297747A1

  公开（公告）日：2015-10-22

  Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L 1 -(A-L 2 )a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L 1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L 2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.
• STABILIZED POLYPEPTIDES AND USES THEREOF
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US20160244494A1

  公开（公告）日：2016-08-25

  The present invention provides inventive stabilized STAT polypeptides, pharmaceutical compositions thereof and methods of making and using inventive stabilized STAT polypeptides.